ATM and lung carcinoma: In cisplatin-resistant lung cancer cells, Ataxia Telangiectasia Mutated (ATM) upregulates the EMT and metastatic capacity of cancer cells by activating the JAK/STAT signaling pathway, thus mediating cell resistance to cisplatin; inhibition of the JAK/STAT pathway by SiRNA significantly reduced the EMT and invasiveness of the resistant cells.